News

The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and

In addition, Marken has begun their unique hybrid service for shipments into Russia for drug storage and distribution and from Russia for biologic sample shipments.  Together, these new

The recommendation is based on the progression-free survival (PFS) and overall survival (OS) primary endpoints of the Phase III PACIFIC trial, and post-hoc subgroup analyses by PD-L1 expression

It is the fourth Sandoz biosimilar approved in Europe in past 18 months, and seventh in total. Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein

Clinically relevant levels were reached after the first injection of PERSERIS without use of a loading dose or any supplemental oral risperidone.1 “Treatment adherence is a major challenge

The pharmaceutical secondary packaging company said that patients can handle their medication intake more easily owing to intelligent, interactive pharmaceutical packaging with integrated electronics. Faller said that its

Under the financial terms, Kite will provide research and development (R&D) funding for the collaboration and Gadeta will be eligible to receive future payments upon achievement of certain

GSK said the committee voted on the basis of data presented that the risk-benefit profile was not adequate to support approval In addition, the committee noted that there

The trial is one of the two phase 1 safety clinical studies of the drug examining its potential to cause dermal irritation. XF-73 is Destiny Pharma’s lead candidate